HEPARIN COFACTOR II/GLYCOSAMINOQLYCAN INTERACTIONS

肝素辅因子II（HCII）是人血浆中的一种糖蛋白， 凝血酶迅速在肝素或硫酸皮肤素的存在下。 在 与抗凝血酶III（ATIII）接触，HCII不抑制因子Xa或 其他凝血蛋白酶。 尽管肝素增加了 无论是HCII还是ATIII，硫酸皮肤素都能特异性激活HCII。 HCII 在许多弥散性血管内凝血患者中， 但在血栓形成患者中正常。 为了更好地了解具体的 HCII、凝血酶和糖胺聚糖之间的相互作用：（1） 肝素HCII结合区结构的测定， 将该结构与高亲和力ATIII-结合 （3）识别激活HCII的细胞类型 和活性细胞蛋白聚糖的表征;（4） 寡糖结合解离常数的测定 HCII;（5）确定了HCII反应位点的氨基酸序列。 HCII活性和凝血酶-HCII复合物的测定。 各种病人。 这些研究可能会提供线索，生理 HCII的功能以及潜在的治疗用途的基础 硫酸皮肤素作为抗凝剂。

Heparin cofactor II (HCII) is a glycoprotein in human plasma that inhibits thrombin rapidly in the presence of heparin or dermatan sulfate. In contract to antithrombin III (ATIII), HCII does not inhibit factor Xa or other coagulation proteases. Although heparin increases the activity of both HCII and ATIII, dermatan sulfate specifically activates HCII. HCII activity is decreased in many patients with disseminated intravascular coagulation and peatic failure but is normal in patients with thrombosis. The following studies will be done to better understand the specific interactions between HCII, thrombin, and glycosaminoglycans: (1) determination of the structure of the HCII-binding region of heparin and comparison of this structure to the high-affinity ATIII-binding ogliosaccharide; (3) identification of types of cells that activate HCII and characterization of the active cellular proteoglycans; (4) determination of dissociation constants for oligosaccharide binding to HCII; (5) determination of the amino acide sequence of the reactive site of HCII; and (6) measurement of HCII activity and thrombin-HCII complex in various patients. These studies may provide clues to the physiological functions of HCII as well as a basis for the potential therapeutic use of dermatan sulfate as an anticoagulant.